Iradimed Co (IRMD)vsNovartis AG ADR (NVS)
IRMD
Iradimed Co
$83.44
-0.32%
HEALTHCARE · Cap: $1.07B
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 67404% more annual revenue ($56.58B vs $83.81M). IRMD leads profitability with a 26.8% profit margin vs 23.9%. NVS appears more attractively valued with a PEG of 2.48. IRMD earns a higher WallStSmart Score of 60/100 (C).
IRMD
Buy60
out of 100
Grade: C
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-81.7%
Fair Value
$56.73
Current Price
$83.44
$26.71 premium
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 31.3%
Every $100 of equity generates 25 in profit
Keeps 27 of every $100 in revenue as profit
17.0% revenue growth
Earnings expanding 24.8% YoY
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
Trading at 11.3x book value
Smaller company, higher risk/reward
Expensive relative to growth rate
Premium valuation, high expectations priced in
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : IRMD
The strongest argument for IRMD centers on Operating Margin, Return on Equity, Profit Margin. Profitability is solid with margins at 26.8% and operating margin at 31.3%. Revenue growth of 17.0% demonstrates continued momentum.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : IRMD
The primary concerns for IRMD are Price/Book, Market Cap, PEG Ratio. A P/E of 47.8x leaves little room for execution misses.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Key Dynamics to Monitor
IRMD profiles as a growth stock while NVS is a declining play — different risk/reward profiles.
IRMD carries more volatility with a beta of 1.12 — expect wider price swings.
IRMD is growing revenue faster at 17.0% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
IRMD scores higher overall (60/100 vs 51/100), backed by strong 26.8% margins and 17.0% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Iradimed Co
HEALTHCARE · MEDICAL DEVICES · USA
IRADIMED CORPORATION develops, manufactures, markets and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories and services in the United States and internationally. The company is headquartered in Winter Springs, Florida.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?